

Claims:

1. A computer system comprising at least one database correlating the presence of at least one mutation in a human immunodeficiency virus (HIV) reverse transcriptase and a change in susceptibility of at least one strain of HIV to a reverse transcriptase inhibitor, comprising at least one record corresponding to a correlation between at least one mutation 194G in said reverse transcriptase, and treatment with at least a reverse transcriptase inhibitor.
2. A method for evaluating the effectiveness of a reverse transcriptase inhibitor as an antiviral therapy for a patient infected with at least one mutant HIV strain comprising:
  - (i) collecting a sample from an HIV-infected patient;
  - (ii) determining whether the sample comprises a nucleic acid encoding HIV reverse transcriptase having at least one mutation 194G;
  - (iii) correlating the presence of said at least one mutation of step (ii) to a change in effectiveness of said reverse transcriptase inhibitor.
3. A method for identifying a drug effective against mutant HIV reverse transcriptase, comprising:
  - (i) providing a HIV reverse transcriptase nucleic acid comprising at least one mutation 194G;
  - (ii) recombining said nucleic acid of step (i) into a proviral nucleic acid deleted for said sequence to generate a recombinant HIV virus;
  - (iii) determining a phenotypic response of said drug to said HIV reverse transcriptase; and
  - (iv) identifying a drug effective against mutant HIV based on the phenotypic response of step (iii) .
4. A method for identifying a drug effective against mutant HIV reverse transcriptase, comprising:
  - (i) providing a HIV reverse transcriptase comprising at least one mutation 194G;
  - (ii) determining the activity of said drug on said HIV reverse transcriptase;
  - (iii) determining the activity of said drug on wild type HIV reverse transcriptase;
  - (iv) determining the ratio of the activity determined in step (iii) over the activity

- determined in step (ii);
- (v) identifying an effective drug against mutant HIV based on the ratio of step (iv).
5. A method for evaluating a change in viral drug susceptibility comprising:
- (i) collecting a sample from an HIV-infected patient;
- 5 (ii) determining whether the sample comprises a HIV reverse transcriptase having at least one mutation 194G;
- (iii) correlating the presence of said at least one mutation of step (ii) to a change in viral drug susceptibility.
- 10 6. A method for evaluating a change in viral drug susceptibility, comprising:
- (i) providing an HIV comprising a reverse transcriptase comprising at least one mutation 194G;
- (ii) determining a phenotypic response of said virus to said drug; and
- (iii) correlating the phenotypic response of step (ii) to a change in viral drug
- 15 susceptibility.
7. A method for evaluating a change in drug effectiveness against mutant HIV reverse transcriptase, comprising:
- (i) providing a HIV reverse transcriptase comprising at least one mutation 194G;
- 20 (ii) determining the activity of said drug on said reverse transcriptase;
- (iii) determining the activity of said drug on wild type HIV reverse transcriptase and;
- (iv) determining the ratio of the activity determined in step (iii) over the activity determined in step (ii);
- 25 (v) identifying an effective drug against mutant HIV based on the ratio of step (iv).
8. A vector for performing phenotypic analysis comprising an HIV sequence having at least one mutation 194G in the HIV reverse transcriptase.
- 30 9. An isolated and purified HIV reverse transcriptase sequence having at least one mutation 194G, wherein said at least one mutation in said sequence correlates to a fold change in susceptibility towards a HIV reverse transcriptase inhibitor.
- 35 10. An isolated and purified oligonucleotide comprising a HIV reverse transcriptase sequence of 5 to 100 bases for in vitro diagnosis of viral drug resistance,

TIP-0015-US

Express Mail Label No. EV 488 942 033 US

characterized in that said oligonucleotide comprises at least one mutation 194G.